Везде
КОНФЛИКТЫ ИНТЕРЕСОВ У ИССЛЕДОВАТЕЛЕЙ И ОРГАНИЗАЦИЙ
Оглавление
Аннотация Оценить Содержание публикации
Библиография Комментарии
Поделиться
QR
Метрика
КОНФЛИКТЫ ИНТЕРЕСОВ У ИССЛЕДОВАТЕЛЕЙ И ОРГАНИЗАЦИЙ
Аннотация
Код статьи
S0869-54150000402-5-1
Тип публикации
Статья
Статус публикации
Опубликовано
Авторы
Лоо Сана  
Выпуск
Выпуск №3
Страницы
69-81
Аннотация
В данной статье автор рассматривает широкий спектр возможных конфликтов интересов в исследованиях, включая те, которые проходят с участием человека. Автор указывает на то, что конфликт интересов это обычное явление, которое может проявляться во многих ситуациях и на многих уровнях исследования. В ситуации, когда конфликт интересов останется неопределенным и нерешенным, это может привести к нарушению исследовательской этики и даже сказаться на достоверности самого исследования. Главная задача всех сторон осознать существование конфликта и научиться управлять им.
Ключевые слова
конфликт интересов, исследовательская этика, решение конфликтов, управление конфликтами, нарушения этики
Классификатор
Дата публикации
01.05.2013
Всего подписок
1
Всего просмотров
460
Оценка читателей
0.0 (0 голосов)
Цитировать Скачать pdf

Библиография



Дополнительные библиографические источники и материалы

    

  1. Ankier 2002 Ankier S.I. Dishonesty, misconduct and fraud in clinical research: An international problem // Journal of International Medical Research. 2002. Vol. 30. P. 357-365.
    2. 

  2. Barnes, Florencio 2002 Barnes M., Florencio P.S. Investigator, IRB, and institutional financial conflicts of interest in human subjects research: Past, present and future // Seton Hall Law Review. 2002. № 32. P. 525-561.
    3. 

  3. Bekelman et al. 2003 Bekelman J.E., Li Y., Gross C.P. Scope and impact of financial conflicts of interest in biomedical research: A systematic review // Journal of the American Medical Association. 2003. Vol. 289. № 4. P. 454-465.
    4. 

  4. Bodenheimer T. 2000 Bodenheimer T. Uneasy alliance: Clinical investigators and the pharmaceutical industry // New England Journal of Medicine. 2000. 342. P. 1539-1543.
    5. 

  5. Campbell et al. 2007 Campbell E.G., Weissman J.S., Ehringhaus S., Rao S.R., Moy B., Feibelmann S., Goold S.D. Institutional academic-industry relationships // Journal of the American Medical Association. 2007. № 298 (15). P. 1779-1786.
    6. 

  6. Code.. Code of Federal Regulations. Title 42: Public Health.
    7. 

  7. Davis et al. 2007 Davis M.S., Riske-Morris M., Diaz S.R. Causal factors implicate din research misconduct: Evidence from ORI case files // Science and Engineering Ethics. 2007. № 13. P. 395-414.
    8. 

  8. DeAngelis C.D. 2000 DeAngelis C.D. Conflict of interest and the public trust // Journal of the American Medical Association. 2000. № 284(17). P. 2237-2238.
    9. 

  9. Ehringhaus et al. 2008 Ehringhaus S.H., Weissman J.S, Sears J.L., Goold S.D., Feibelman S., Campbell E.G. Responses of medical schools to institutional conflicts of interest // Journal of the American Medical Association. 2008. № 299. P. 665-671.
    10. 

  10. FMH 2001 Federal Ministry of Health. Report of the investigation committee on the clinical trial of Trovan by Pfizer, Kano. [Электронный ресурс]: http://www.washingtonpost.com/wp-srv/world/ documents/Clinical_Trial_Report. pdf. Дата обращения: 12.05.2012.
    11. 

  11. Fee splitting.. 2000 Fee splitting: Referrals to health care facilities (Opinion E-603) // American Medical Association Council on Ethical and Judicial Affairs, Code of medical ethics: current opinions. Chicago; Illinois, 2000.
    12. 

  12. Finder's fees.. 1994 Finder's fees: Payment for the referral of patients to clinical research studies (Report № 65) // American Medical Association, Council on Ethical and Judicial Affairs Chicago; Illinois, 1994.
    13. 

  13. Fox J. 2000 Fox J. Gene-therapy death prompts broad civil lawsuit // Nature Biotechnology. 2000. № 18. P. 1136.
    14. 

  14. Gottweis, Triendl 2006 Gottweis H., Triendl R. South Korean policy failure and the Hwang debacle // Nature and Bioetechnology. 2006. № 24 (2). P. 141-143.
    15. 

  15. Habiba, Evans 2002 Habiba M., Evans M. The inter-role confidentiality conflict in recruitment for clinical research // Journal of Medicine and Philosophy. 2002. № 27(5). P. 565-587.
    16. 

  16. Iltis 2005 Iltis A.S. Timing invitations to participate in clinical research: Preliminary versus informed consent // Journal of Medicine and Philosophy. 2005. № 30. P. 89-106.
    17. 

  17. Institute of Medicine. (2009). Conflict of interest in medical research, education, and practice. Washington, D.C: National Academies Press. Jones 2009 Jones N. Ghosts still present in the medical machine // Nature. 2009. № 461. P. 325.
    18. 

  18. Judson 2004 Judson H. The great betrayal: Fraud in science. Orlando: Harcourt, Inc., 2004.
    19. 

  19. Klitzman et al. 2010 Klitzman R., Chin L.J., Rifai-Bishjawish H., Kleinert K., Leu C.-S. Disclosures of funding sources and conflicts of interest in published HIV/AIDS research conducted in developing countries // Journal of Medical Ethics. 2010. № 36. P. 505-510.
    20. 

  20. Korn 2000 Korn D. Conflicts of interest in biomedical research // Journal of the American Medical Association. 2000. № 284. P. 2234-2237.
    21. 

  21. Krimsky et al. 2001 Krimsky S., Rothernberg L.S. Conflict of interest policies in science and medical journals: Editorial practices and author disclosures // Science and Engineering Ethics. 2001. № 7. P. 205-218.
    22. 

  22. Lemmens, Miller 2003 Lemmens T., Miller P.B. The human subjects trade: Ethical and legal issues surrounding recruitment incentives // Journal of Law Medicine and Ethics. 2003. № 31. P. 398418.
    23. 

  23. Liang, Mackey T. 2010 Liang B.A., Mackey T. Confronting conflict: Addressing institutional conflicts of interest in academic medical centers // American Journal of law Medicine. 2010. J№ 36. P. 136187.
    24. 

  24. Milner 2010 -Milner J. E. Letter Re: Retention for Consulting and Expert Witness Services ("Retention Agreement") April 20, 2010 Transocean Horizon Incident, Brunini, Grantham, Grower and Hewes, PLLC, Jackson, Mississippi.
    25. 

  25. Moses, Martin 2001 Moses H. Martin J.B. Academic relationships with industry // Journal of the American Medical Association. 2001. № 285. Р. 933-935.
    26. 

  26. Nairn 1993 Nairn T.A. The use of Zairian children in HIV vaccine experimentation: A cross-cultural study in medical ethics // The Annual of the Society of Christian Ethics. 1993. № 13. P. 223243.
    27. 

  27. Raines 2010 Raines B. BP buys up Gulf scientists for legal defense, roiling academic community. Press-Register, July 16. [Электронный ресурс]: http://blog.al.com/live/2010/07/bp_buys_up_ gulf_scientists_for.html. Дата обращения: 12.11. 2010.
    28. 

  28. Review Panel.. 2002 Review Panel, University of Vermont College of Medicine. Investigation report. Burlington, 2002.
    29. 

  29. Rothman 2008 Rothman D.J. Academic medical centers and financial conflicts of interest // Journal of the American Medical Association. 2008. № 299. P. 695-697.
    30. 

  30. Sax 2012 Sax J.K. Financial conflicts of interest in science // Annals of Health Law. № 21. P. 291327.
    31. 

  31. Shipp 1992 Shipp A.C. How to control conflict of interest // Biomedical research: Collaboration and conflict of interest / R.J.Q Porter and T.E. Malone (eds.). P. 163-184.
    32. 

  32. Slingsby et al. 2006 Slingsby B.T., Kodama S., and Akayabashi A. Scientific misconduct in Japan: The present paucity of oversight policy // Cambridge Quarterly of healthcare Ethics. 2006. № 15. P. 294-297.
    33. 

  33. P. 294-297. Statement.. 2012 Statement of Defence. Attorney General of Kano State v. Pfizer International Incorporated et al. High Court of Kano State // Suit № K/233/2007. [Электронный ресурс]: http://www.pfizer.com/files/news/trovan_litigation_statement _defense.pdf. Дата обращения: 13.05.2012
    34. 

  34. Stephens 2000 Stephens J. The body hunters: Where profits and lives hang in balance; Finding an abundance of subjects and lack of oversight abroad, big drug companies test offshore to speed products to market // Washington Post. 2000. December, 17. [Электронный ресурс]: http://www.washingtonpost.com/wp-dyn/content/story/2008/ 10/01/ST2008100101390. html?sid=ST2008100101390 Дата обращения: 12.05. 2012.
    35. 

  35. Stolberg 1999 Stolberg S. F.D.A. officials fault Penn team in gene therapy death. New York Times. 1999. December, 9. A23.
    36. 

  36. Thomson 1993 Thomson D.Understanding financial conflicts of interest // New England Journal of Medicine. 1993. № 329. P. 573-578. USBPA 2000 University and Small Business Procedures Act, 35 U.S.C. § 200. 2000.
    37. 

  37. US Department.. 2010 United States Department of Justice. (2005). Press release: U.S. settles case of gene therapy study that ended with teen's death. [Электронный ресурс]: http://www. durrelllaw.com/UofPSettlementReleaseFinal.pdf.
    38. 

  38. Wadman M. 1996 Wadman M. Drug company "suppressed" publication of research // Nature Vol. 381, № 6577. P. 4.
    39. 

  39. Weinfurt et al. 2006 Weinfurt K.P., Friedman J.Y., Dinan M.A., Allsbrook J.S., Hall M.A., Dhillon J.K., and Sugarman J. Disclosing conflicts of interest in clinical research: Views of institutional review boards, conflict of interest committees, and investigators // Journal of Law, Medicine, and Ethics. 2006. Vol. 34, № 3. P. 581-591.
    40. 

  40. Xin 2006 Xin H. Scientific misconduct: Scandals shake Chinese science // Science. 2006. Vol. 312, № 5779. P. 1464-1466.
    41.

Комментарии

Сообщения не найдены

Написать отзыв
Перевести